Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of Th1/Th2 and Th17/Treg cells in a murine acute graft-versus-host disease model

Cell Transplantation

Volumn 23, Issue 6, 2014, Pages 703-714

  Lim, Jung Yeon ^a   Park, Min Jung ^a   Im, Keon Il ^a   Kim, Nayoun ^a   Jeon, Eun Joo ^a   Kim, Eun Jung ^a   Cho, Mi La ^a   Cho, Seok Goo ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Allogeneic bone marrow transplantation; Graft versus host disease (GVHD); Mesenchymal stem cells (MSCs); Regulatory T cell

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL; ACUTE DISEASE; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; GRAFT VS HOST DISEASE; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; SPLEEN; TRANSPLANTATION;

ACUTE DISEASE; ANIMALS; BONE MARROW CELLS; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; IMMUNOMODULATION; INTERLEUKIN-10; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHENOTYPE; SPLEEN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84898917571     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368913X664577     Document Type: Article

References (46)

1. Aggarwal, S.; Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815-1822; 2005.
2. Arima, N.; Nakamura, F.; Fukunaga, A.; Hirata, H.; Machida, H.; Kouno, S.; Ohgushi, H. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: A pilot study. Cytotherapy 12(2):265-268; 2010.
3. Bayer, A. L.; Jones, M.; Chirinos, J.; de Armas, L.; Schreiber, T. H.; Malek, T. R.; Levy, R. B. Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood 113(3):733-743; 2009.
4. Benito, A. I.; Furlong, T.; Martin, P. J.; Anasetti, C.; Appelbaum, F. R.; Doney, K.; Nash, R. A.; Papayannopoulou, T.; Storb, R.; Sullivan, K. M.; Witherspoon, R.; Deeg, H. J. Sirolimus (rapamycin) for the treatment of steroidrefractory acute graft-versus-host disease. Transplantation 72(12):1924-1929; 2001.
5. Carlson, M. J.; West, M. L.; Coghill, J. M.; Panoskaltsis-Mortari, A.; Blazar, B. R.; Serody, J. S. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113(6):1365-1374; 2009.
6. Carpenter, P. A.; Lowder, J.; Johnston, L.; Frangoul, H.; Khoury, H.; Parker, P.; Jerome, K. R.; McCune, J. S.; Storer, B.; Martin, P.; Appelbaum, F.; Abonour, R.; Westervelt, P.; Anasetti, C. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 11(6):465-471; 2005.
7. Di Nicola, M.; Carlo-Stella, C.; Magni, M.; Milanesi, M.; Longoni, P. D.; Matteucci, P.; Grisanti, S.; Gianni, A. M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10):3838-3843; 2002.
8. Engela, A. U.; Baan, C. C.; Peeters, A. M.; Weimar, W.; Hoogduijn, M. J. Interaction between adipose-tissue derived mesenchymal stem cells and regulatory T cells. Cell Transplant. 22(1):41-54; 2013
9. English, K.; Mahon, B. P. Allogeneic mesenchymal stem cells: Agents of immune modulation. J. Cell. Biochem. 112(8):1963-1968; 2011.
10. Fang, J.; Hu, C.; Hong, M.; Wu, Q.; You, Y.; Zhong, Z.; Li, W.; Zou, P.; Hu, Y.; Xia, L. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant. 18(5): 754-762; 2012.
11. Fukui, J.; Inaba, M.; Ueda, Y.; Miyake, T.; Hosaka, N.; Kwon, A. H.; Sakaguchi, Y.; Tsuda, M.; Omae, M.; Kamiyama, Y.; Ikehara, S. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells. Stem Cells 25(6):1595-1601; 2007.
12. Gaidot, A.; Landau, D. A.; Martin, G. H.; Bonduelle, O.; Grinberg-Bleyer, Y.; Matheoud, D.; Gregoire, S.; Baillou, C.; Combadiere, B.; Piaggio, E.; Cohen, J. L. Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. Blood 117(10):2975-2983; 2011.
13. Graziani, F.; Van Lint, M. T.; Dominietto, A.; Raiola, A. M.; Di Grazia, C.; Lamparelli, T.; Gualandi, F.; Bregante, S.; Fiorone, M.; Bruno, B.; Bacigalupo, A. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica 87(9):973-978; 2002.
14. Guy-Grand, D.; Vassalli, P. Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. J. Clin. Invest. 77(5):1584-1595; 1986.
15. Horwitz, D. A.; Zheng, S. G.; Gray, J. D. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 29(9):429-435; 2008.
16. Jeon, E. J.; Yoon, B. Y.; Lim, J. Y.; Oh, H. J.; Park, H. S.; Park, M. J.; Lim, M. A.; Park, M. K.; Kim, K. W.; Cho, M. L.; Cho, S. G. Adoptive transfer of all-trans-retinalinduced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model. Autoimmunity 45(6):460-469; 2012.
17. Joo, S. Y.; Cho, K. A.; Jung, Y. J.; Kim, H. S.; Park, S. Y.; Choi, Y. B.; Hong, K. M.; Woo, S. Y.; Seoh, J. Y.; Cho, S. J.; Ryu, K. H. Mesenchymal stromal cells inhibit graftversus-host disease of mice in a dose-dependent manner. Cytotherapy 12(3):361-370; 2010.
18. Komatsu, N.; Mariotti-Ferrandiz, M. E.; Wang, Y.; Malissen, B.; Waldmann, H.; Hori, S. Heterogeneity of natural Foxp3+ T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc. Natl. Acad. Sci. USA 106(6):1903-1908; 2009.
19. Le Blanc, K.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, I.; Lanino, E.; Sundberg, B.; Bernardo, M. E.; Remberger, M.; Dini, G.; Egeler R. M.; Bacigalupo, A.; Fibbe, W. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371(9624):1579-1586; 2008.
20. Le Blanc, K.; Rasmusson, I.; Sundberg, B.; Gotherstrom, C.; Hassan, M.; Uzunel, M.; Ringden, O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439-1441; 2004.
21. Liu, H.; Lu, K.; MacAry, P. A.; Wong, K. L.; Heng, A.; Cao, T.; Kemeny, D. M. Soluble molecules are key in maintaining the immunomodulatory activity of murine mesenchymal stromal cells. J. Cell Sci. 125(Pt 1):200-208; 2012.
22. Maccario, R.; Podesta, M.; Moretta, A.; Cometa, A.; Comoli, P.; Montagna, D.; Daudt, L.; Ibatici, A.; Piaggio, G.; Pozzi, S.; Frassoni, F.; Locatelli, F. Interaction of human mesenchymal stem cells with cells involved in alloantigenspecific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90(4):516-525; 2005.
23. MacMillan, M. L.; Weisdorf, D. J.; Davies, S. M.; DeFor, T. E.; Burns, L. J.; Ramsay, N. K.; Wagner, J. E.; Blazar, B. R. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol. Blood Marrow Transplant. 8(1):40-46; 2002.
24. Mao, F.; Xu, W. R.; Qian, H.; Zhu, W.; Yan, Y. M.; Shao, Q. X.; Xu, H. X. Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflamm. Res. 59(3):219-225; 2010.
25. Marigo, I.; Dazzi, F. The immunomodulatory properties of mesenchymal stem cells. Semin. Immunopathol. 33(6): 593-602; 2011.
26. Mielcarek, M.; Storb, R.; Georges, G. E.; Golubev, L.; Nikitine, A.; Hwang, B.; Nash, R. A.; Torok-Storb, B. Mesenchymal stromal cells fail to prevent acute graftversus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation. Biol. Blood Marrow Transplant. 17(2):214-225; 2011.
27. Muller, I.; Kordowich, S.; Holzwarth, C.; Isensee, G.; Lang, P.; Neunhoeffer, F.; Dominici, M.; Greil, J.; Handgretinger, R. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol. Dis. 40(1):25-32; 2008.
28. Pan, B.; Zeng, L.; Cheng, H.; Song, G.; Chen, C.; Zhang, Y.; Li, Z.; Xu, K. Altered balance between Th1 and Th17 cells in circulation is an indicator for the severity of murine acute GVHD. Immunol. Lett. 142(1-2):48-54; 2012.
29. Park, M. J.; Park, H. S.; Cho, M. L.; Oh, H. J.; Cho, Y. G.; Min, S. Y.; Chung, B. H.; Lee, J. W.; Kim, H. Y.; Cho, S. G. Transforming growth factor beta-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum. 63(6):1668-1680; 2011.
30. Perfetti, P.; Carlier, P.; Strada, P.; Gualandi, F.; Occhini, D.; Van Lint, M. T.; Ibatici, A.; Lamparelli, T.; Bruno, B.; Raiola, A. M.; Dominietto, A.; Di Granzia, C.; Breqante, S.; Zia, S.; Ferrari, G. M.; Stura, P.; Pogliani, E.; Bacigalupo, A. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant. 42(9):609-617; 2008.
31. Remberger, M.; Aschan, J.; Barkholt, L.; Tollemar, J.; Ringden, O. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin. Transplant. 15(3):147-153; 2001.
32. Riley, J. L.; June, C. H.; Blazar, B. R. Human T regulatory cell therapy: Take a billion or so and call me in the morning. Immunity 30(5):656-665; 2009.
33. Schliesser, U.; Streitz, M.; Sawitzki, B. Tregs: Application for solid-organ transplantation. Curr. Opin. Organ Transplant. 17(1):34-41; 2012.
34. Soleimani, M.; Nadri, S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat. Protoc. 4(1):102-106; 2009.
35. Soleymaninejadian, E.; Pramanik, K.; Samadian, E. Immunomodulatory properties of mesenchymal stem cells: Cytokines and factors. Am. J. Reprod. Immunol. 67(1):1-8; 2012.
36. Sudres, M.; Norol, F.; Trenado, A.; Gregoire, S.; Charlotte, F.; Levacher, B.; Lataillade, J. J.; Bourin, P.; Holy, X.; Vernant, J. P.; Klatzmann, D.; Cohen, J. L. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 176(12):7761-7767; 2006.
37. Szebeni, J.; Wang, M. G.; Pearson, D. A.; Szot, G. L.; Sykes, M. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease. Transplantation 58(12):1385-1393; 1994.
38. Teshima, T. Th1 and Th17 join forces for acute GVHD. Blood 118(18):4765-4767; 2011.
39. Ukena, S. N.; Velaga, S.; Geffers, R.; Grosse, J.; Baron, U.; Buchholz, S.; Stadler, M.; Bruder, D.; Ganser, A.; Franzke, A. Human regulatory T cells in allogeneic stem cell transplantation. Blood 118(13):e82-92; 2011.
40. Veerapathran, A.; Pidala, J.; Beato, F.; Yu, X. Z.; Anasetti, C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood 118(20):5671-5680; 2011.
41. Westin, J. R.; Saliba, R. M.; De Lima, M.; Alousi, A.; Hosing, C.; Qazilbash, M. H.; Khouri, I. F.; Shpall, E. J.; Anderlini, P.; Rondon, G.; Andersson, B. S.; Champlin, R.; Couriel, D. R. Steroid-refractory acute GVHD: Predictors and outcomes. Adv. Hematol. 2011:601953; 2011.
42. Xhaard, A.; Rocha, V.; Bueno, B.; de Latour, R. P.; Lenglet, J.; Petropoulou, A.; Rodriguez-Otero, P.; Ribaud, P.; Porcher, R.; Socie, G.; Robin, M. Steroid-refractory acute GVHD: Lack of long-term improved survival using new generation anticytokine treatment. Biol. Blood Marrow Transplant. 18(3):406-413; 2012.
43. Yang, X. O.; Nurieva, R.; Martinez, G. J.; Kang, H. S.; Chung, Y.; Pappu, B. P.; Shah, B.; Chang, S. H.; Schluns, K. S.; Watowich, S. S.; Feng, X. H.; Jetten, A. M.; Dong, C. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29(1):44-56; 2008.
44. Yi, T.; Chen, Y.; Wang, L.; Du, G.; Huang, D.; Zhao, D.; Johnston, H.; Young, J.; Todorov, I.; Umetsu, D. T.; Chen, L.; Iwakura, Y.; Kandee, F.; Forman, S.; Zeng, D. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 114(14):3101-3112; 2009.
45. Yu, Y.; Wang, D.; Liu, C.; Kaosaard, K.; Semple, K.; Anasetti, C.; Yu, X. Z. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORgammat in mice. Blood 118(18):5011-5020; 2011.
46. Zhao, J.; Li, R.; He, J.; Shi, J.; Long, L.; Li, Z. Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells. Rheumatol. Int. 29(1):9-16; 2008.